Selvita

Selvita EBITDA per Share

The EBITDA per Share of Selvita (SLV.WA) as of Nov 19, 2026 is 0.68 PLN. In the previous year, EBITDA per Share was 2.87 PLN — a change of -76.17% (lower).

EBITDA per Share

0.68PLN

YoY

-76.17%

Last updated:

EBITDA per Share of Selvita is 2025 0.68 PLN. EBITDA per Share of Selvita was 2024 2.87 PLN. It decreases by -76.17% lower compared to the previous year.

The Selvita EBITDA per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Share
Date
EBITDA per Share
Jan 1, 2018
0.63 PLN
Jan 1, 2019
0.50 PLN
Jan 1, 2020
1.80 PLN
Jan 1, 2021
2.92 PLN
Jan 1, 2022
4.37 PLN
Jan 1, 2023
6.25 PLN
Jan 1, 2024
2.87 PLN
Jan 1, 2025
0.68 PLN
The Selvita EBITDA per Share history
YEAREBITDA per ShareYoY
0.68PLN-76.17%
2.87PLN-54.16%
6.25PLN+43.00%
4.37PLN+49.81%
2.92PLN+62.00%
1.80PLN+259.48%
0.50PLN-20.89%
0.63PLN+73.53%
0.37PLN-651.98%
-0.07PLN-158.56%
0.11PLN—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Selvita Stock analysis

What does Selvita do? Selvita SA generates revenue through multidisciplinary solutions for drug discovery, regulatory studies, and research and development. The company provides early-stage drug discovery support, including target validation and clinical candidate selection, alongside drug testing and bioanalytical services such as method development, stability studies, and quality control testing. Its clients include pharmaceutical companies and research institutions across Europe and the United States, which rely on Selvita's expertise for comprehensive project support throughout the drug development lifecycle. The firm's services span the entire drug discovery process, from initial target identification to preclinical research and clinical candidate selection. By offering end-to-end solutions, Selvita caters to clients seeking efficient and reliable support in complex research phases. Its collaborations with European and American research institutes and universities further strengthen its position in the biotech and pharmaceutical sectors. Selvita SA's business model focuses on delivering specialized scientific services tailored to the needs of clients in drug development. The company's offerings cover all critical stages of the drug discovery process, ensuring clients can advance their projects with minimal delays. This approach allows Selvita to maintain strong relationships with its key clients in the pharmaceutical and research communities. Selvita is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Selvita stock

EBITDA per Share of Selvita is 0.68 PLN in 2025.

EBITDA per Share of Selvita changed from 2.87 PLN to 0.68 PLN, representing a -76.17% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Share Selvita since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Selvita

All Key Metrics — Selvita